Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake

[1]  Francesco Mori,et al.  miR-142-3p is a key regulator of IL-1β-dependent synaptopathy in neuroinflammation. , 2017, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[2]  Ignacio S. Caballero,et al.  Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor , 2016, Proceedings of the National Academy of Sciences.

[3]  P. Rosenberg,et al.  GLT-1: The elusive presynaptic glutamate transporter , 2016, Neurochemistry International.

[4]  D. Centonze,et al.  Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis , 2016, Journal of Neuroinflammation.

[5]  R. Ransohoff.  A polarizing question: do M1 and M2 microglia exist? , 2016, Nature Neuroscience.

[6]  D. Centonze,et al.  Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis , 2015, Nature Reviews Neurology.

[7]  A. C. Fontana.  Current approaches to enhance glutamate transporter function and expression , 2015, Journal of neurochemistry.

[8]  M. Aschner,et al.  Transcriptional Regulation of the Astrocytic Excitatory Amino Acid Transporter 1 (EAAT1) via NF-κB and Yin Yang 1 (YY1)* , 2015, The Journal of Biological Chemistry.

[9]  Kou Takahashi,et al.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease , 2015, Cellular and Molecular Life Sciences.

[10]  R. Gold,et al.  Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis , 2014, Journal of Neuroimmunology.

[11]  S. Nelson,et al.  In vivo evidence of glutamate toxicity in multiple sclerosis , 2014, Annals of neurology.

[12]  M. O’Banion,et al.  Neuroinflammation and M2 microglia: the good, the bad, and the inflamed , 2014, Journal of Neuroinflammation.

[13]  W. Brück,et al.  Laquinimod reduces neuroaxonal injury through inhibiting microglial activation , 2014, Annals of clinical and translational neurology.

[14]  Milos Kostic,et al.  The role of glutamate and its receptors in multiple sclerosis , 2014, Journal of Neural Transmission.

[15]  D. Arnold,et al.  A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis , 2014, Journal of Neurology.

[16]  Q. Kan,et al.  Matrine regulates glutamate-related excitotoxic factors in experimental autoimmune encephalomyelitis , 2014, Neuroscience Letters.

[17]  Kyuwon Lee,et al.  Yin Yang 1 Is a Repressor of Glutamate Transporter EAAT2, and It Mediates Manganese-Induced Decrease of EAAT2 Expression in Astrocytes , 2014, Molecular and Cellular Biology.

[18]  N. Rothwell,et al.  The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial , 2014, Journal of Neuroinflammation.

[19]  Rhusheet P Patel,et al.  Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis , 2013, Brain and behavior.

[20]  M. Filippi,et al.  Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  S. Hauser,et al.  Multiple sclerosis: Prospects and promise , 2013, Annals of neurology.

[22]  Kyuwon Lee,et al.  cAMP Response Element-binding Protein (CREB) and Nuclear Factor κB Mediate the Tamoxifen-induced Up-regulation of Glutamate Transporter 1 (GLT-1) in Rat Astrocytes* , 2013, The Journal of Biological Chemistry.

[23]  D. Centonze,et al.  Interleukin-1β Alters Glutamate Transmission at Purkinje Cell Synapses in a Mouse Model of Multiple Sclerosis , 2013, The Journal of Neuroscience.

[24]  D. Centonze,et al.  Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis , 2013, Multiple sclerosis.

[25]  F. Zipp,et al.  Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. , 2013, Brain : a journal of neurology.

[26]  Puneet Kumar,et al.  Excitotoxicity: bridge to various triggers in neurodegenerative disorders. , 2013, European journal of pharmacology.

[27]  R. Saada,et al.  Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis , 2012, Journal of Neuroimmunology.

[28]  M. Aschner,et al.  Estrogen Attenuates Manganese-Induced Glutamate Transporter Impairment in Rat Primary Astrocytes , 2012, Neurotoxicity Research.

[29]  C. Wegner,et al.  Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination , 2012, Acta Neuropathologica.

[30]  D. Centonze,et al.  GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis , 2012, Neurobiology of Disease.

[31]  M. Filippi,et al.  Placebo-controlled trial of oral laquinimod for multiple sclerosis. , 2012, The New England journal of medicine.

[32]  M. Rattray,et al.  Riluzole elevates GLT-1 activity and levels in striatal astrocytes , 2012, Neurochemistry International.

[33]  P. Fisher,et al.  Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics , 2011, Journal of cellular physiology.

[34]  C. Wegner,et al.  Insight into the mechanism of laquinimod action , 2011, Journal of the Neurological Sciences.

[35]  D. Centonze,et al.  The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis , 2010, Cell Death and Differentiation.

[36]  Camille J. Olechowski,et al.  A diminished response to formalin stimulation reveals a role for the glutamate transporters in the altered pain sensitivity of mice with experimental autoimmune encephalomyelitis (EAE) , 2010, PAIN.

[37]  J. G. Bjaalie,et al.  The concentrations and distributions of three C-terminal variants of the GLT1 (EAAT2; slc1a2) glutamate transporter protein in rat brain tissue suggest differential regulation , 2009, Neuroscience.

[38]  S. Ozawa,et al.  Functions of glutamate transporters in cerebellar Purkinje cell synapses , 2009, Acta physiologica.

[39]  L. Strużyńska,et al.  Expression of glutamate transporters GLT-1 and GLAST in different regions of rat brain during the course of experimental autoimmune encephalomyelitis , 2008, Neuroscience.

[40]  G. Comi,et al.  Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study , 2008, The Lancet.

[41]  P. Fisher,et al.  Mechanism of Ceftriaxone Induction of Excitatory Amino Acid Transporter-2 Expression and Glutamate Uptake in Primary Human Astrocytes* , 2008, Journal of Biological Chemistry.

[42]  J. Sepulcre,et al.  Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis , 2008, Journal of Neuroimmunology.

[43]  M. Robinson,et al.  The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention , 2007, Neurochemistry International.

[44]  R. Mutani,et al.  Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage , 2007, Journal of neuropathology and experimental neurology.

[45]  E. López-Bayghen,et al.  Glutamate‐dependent transcriptional regulation of GLAST/EAAT1: a role for YY1 , 2007, Journal of neurochemistry.

[46]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[47]  Yuan-Fong Lin,et al.  Translational Control of Glial Glutamate Transporter EAAT2 Expression* , 2007, Journal of Biological Chemistry.

[48]  A. Hazell,et al.  Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury , 2006, Neurochemistry International.

[49]  O. Hurtado,et al.  A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke , 2006, The Journal of experimental medicine.

[50]  J. Dunlop.  Glutamate-based therapeutic approaches: targeting the glutamate transport system. , 2006, Current opinion in pharmacology.

[51]  F. Barkhof,et al.  Treatment with laquinimod reduces development of active MRI lesions in relapsing MS , 2005, Neurology.

[52]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[53]  E. López-Bayghen,et al.  Glutamate down-regulates GLAST expression through AMPA receptors in Bergmann glial cells. , 2003, Brain research. Molecular brain research.

[54]  Masahiko Watanabe,et al.  Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[55]  D. Pitt,et al.  Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage , 2001, Annals of neurology.

[56]  A. Ludolph,et al.  The EAAT2 (GLT-1) gene in motor neuron disease: absence of mutations in amyotrophic lateral sclerosis and a point mutation in patients with hereditary spastic paraplegia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[57]  P. Rosenberg,et al.  Dihydrokainate‐sensitive neuronal glutamate transport is required for protection of rat cortical neurons in culture against synaptically released glutamate , 1998, The European journal of neuroscience.

[58]  J. Storm-Mathisen,et al.  Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  M. Robinson,et al.  Transcriptional Regulation of Glutamate Transporters: From Extracellular Signals to Transcription Factors. , 2016, Advances in pharmacology.

[60]  G. Comi,et al.  Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. , 2012, The American journal of pathology.

[61]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.